11.92 USD
+0.07 (+0.59%)
11.92 USD
0 (0%)
NEO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 100 industry peers in the Health Care Providers & Services industry. The financial health of NEO is average, but there are quite some concerns on its profitability. NEO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NEO had positive earnings in the past year.
NEO had a positive operating cash flow in the past year.
NEO had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NEO reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -8.25%, NEO is doing worse than 71.00% of the companies in the same industry.
With a Return On Equity value of -13.54%, NEO is not doing good in the industry: 62.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.25% | ||
| ROE | -13.54% | ||
| ROIC | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NEO (43.46%) is better than 73.00% of its industry peers.
NEO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NEO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
2. Health
2.1 Basic Checks
NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NEO has been increased compared to 1 year ago.
The number of shares outstanding for NEO has been increased compared to 5 years ago.
Compared to 1 year ago, NEO has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 1.83 indicates that NEO is not a great score, but indicates only limited risk for bankruptcy at the moment.
NEO's Altman-Z score of 1.83 is in line compared to the rest of the industry. NEO outperforms 44.00% of its industry peers.
NEO has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NEO (0.41) is better than 66.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.83 |
ROIC/WACCN/A
WACC7.59%
2.3 Liquidity
NEO has a Current Ratio of 3.91. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
NEO has a Current ratio of 3.91. This is amongst the best in the industry. NEO outperforms 91.00% of its industry peers.
NEO has a Quick Ratio of 3.62. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 3.62, NEO belongs to the best of the industry, outperforming 91.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.11% over the past year.
Measured over the past years, NEO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -20.25% on average per year.
NEO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.10%.
NEO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.07% yearly.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%-40%
Revenue 1Y (TTM)10.1%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%11.9%
3.2 Future
The Earnings Per Share is expected to grow by 45.70% on average over the next years. This is a very strong growth
Based on estimates for the next years, NEO will show a quite strong growth in Revenue. The Revenue will grow by 9.43% on average per year.
EPS Next Y-11.19%
EPS Next 2Y29.43%
EPS Next 3Y53.34%
EPS Next 5Y45.7%
Revenue Next Year9.58%
Revenue Next 2Y9.73%
Revenue Next 3Y9.56%
Revenue Next 5Y9.43%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 119.20 indicates a quite expensive valuation of NEO.
NEO's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 26.55. NEO is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 71.16, the valuation of NEO can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as NEO.
When comparing the Price/Forward Earnings ratio of NEO to the average of the S&P500 Index (23.78), we can say NEO is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 119.2 | ||
| Fwd PE | 71.16 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NEO's earnings are expected to grow with 53.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.43%
EPS Next 3Y53.34%
5. Dividend
5.1 Amount
NEO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
11.92
+0.07 (+0.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners101.79%
Inst Owner Change1.24%
Ins Owners1.15%
Ins Owner Change-0.02%
Market Cap1.54B
Revenue(TTM)709.16M
Net Income(TTM)-113.47M
Analysts71.58
Price Target12.58 (5.54%)
Short Float %6.59%
Short Ratio2.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.29%
Min EPS beat(2)31.6%
Max EPS beat(2)40.97%
EPS beat(4)4
Avg EPS beat(4)51.9%
Min EPS beat(4)31.6%
Max EPS beat(4)100%
EPS beat(8)8
Avg EPS beat(8)207.03%
EPS beat(12)12
Avg EPS beat(12)159.81%
EPS beat(16)16
Avg EPS beat(16)125.04%
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.73%
Max Revenue beat(2)1.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.22%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)1.18%
Revenue beat(8)4
Avg Revenue beat(8)-0.08%
Revenue beat(12)8
Avg Revenue beat(12)2.05%
Revenue beat(16)10
Avg Revenue beat(16)1.77%
PT rev (1m)22.77%
PT rev (3m)28.59%
EPS NQ rev (1m)2.03%
EPS NQ rev (3m)-12.46%
EPS NY rev (1m)1.65%
EPS NY rev (3m)-3.45%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)-0.18%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 119.2 | ||
| Fwd PE | 71.16 | ||
| P/S | 2.17 | ||
| P/FCF | N/A | ||
| P/OCF | 112.95 | ||
| P/B | 1.84 | ||
| P/tB | 77.96 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.1
EY0.84%
EPS(NY)0.17
Fwd EY1.41%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)0.11
OCFY0.89%
SpS5.48
BVpS6.48
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.25% | ||
| ROE | -13.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.46% | ||
| FCFM | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 44.15% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.62 | ||
| Altman-Z | 1.83 |
F-Score4
WACC7.59%
ROIC/WACCN/A
Cap/Depr(3y)46.9%
Cap/Depr(5y)68.48%
Cap/Sales(3y)5.71%
Cap/Sales(5y)7.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%-40%
EPS Next Y-11.19%
EPS Next 2Y29.43%
EPS Next 3Y53.34%
EPS Next 5Y45.7%
Revenue 1Y (TTM)10.1%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%11.9%
Revenue Next Year9.58%
Revenue Next 2Y9.73%
Revenue Next 3Y9.56%
Revenue Next 5Y9.43%
EBIT growth 1Y-6.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year146.43%
EBIT Next 3Y41.6%
EBIT Next 5Y28.43%
FCF growth 1Y65.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y158.31%
OCF growth 3YN/A
OCF growth 5Y-21.37%
NEOGENOMICS INC / NEO FAQ
What is the fundamental rating for NEO stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEO.
What is the valuation status of NEOGENOMICS INC (NEO) stock?
ChartMill assigns a valuation rating of 1 / 10 to NEOGENOMICS INC (NEO). This can be considered as Overvalued.
How profitable is NEOGENOMICS INC (NEO) stock?
NEOGENOMICS INC (NEO) has a profitability rating of 1 / 10.
What are the PE and PB ratios of NEOGENOMICS INC (NEO) stock?
The Price/Earnings (PE) ratio for NEOGENOMICS INC (NEO) is 119.2 and the Price/Book (PB) ratio is 1.84.
Can you provide the financial health for NEO stock?
The financial health rating of NEOGENOMICS INC (NEO) is 5 / 10.